Inclusion Criteria:

- Subjects with Philadelphia chromosome positive (PH+) or the fused gene BCR/ABL
positive (BCR/ABL+) accelerated phase chronic myeloid leukemia (CML) whose disease
has primary or acquired hematologic resistance to imatinib mesylate or who are
intolerant of imatinib mesylate.

- Subjects must have had prior exposure to imatinib. However, imatinib mesylate does
not need to be their most recent CML treatment prior to coming on this study.

- Men and women, 18 years of age or older.

- Adequate hepatic function.

- Adequate renal function.

- Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for a period of least 1
month before and at least 3 months after the study in such a manner that the risk of
pregnancy is minimized.

Exclusion Criteria:

- Women who are pregnant or breastfeeding.

- Subjects who are eligible and willing to undergo transplantation during the screening
period.

- A serious uncontrolled medical disorder or active infection that would impair the
ability of the subjects to receive protocol therapy.

- Uncontrolled or significant cardiovascular disease.

- Medications that increase bleeding risk.

- Medications that change heart rhythms.

- Dementia or altered mental status that would prohibit the understanding or rendering
of informed consent.

- History of significant bleeding disorder unrelated to CML.

- Concurrent incurable malignancy other than CML.

- Evidence of organ dysfunction or digestive dysfunction that would prevent
administration of study therapy.

- Prior therapy with dasatinib (BMS-354825).

- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (e.g., infectious disease) illness must
not be enrolled into this study.